PA8568001A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
PA8568001A1
PA8568001A1 PA20038568001A PA8568001A PA8568001A1 PA 8568001 A1 PA8568001 A1 PA 8568001A1 PA 20038568001 A PA20038568001 A PA 20038568001A PA 8568001 A PA8568001 A PA 8568001A PA 8568001 A1 PA8568001 A1 PA 8568001A1
Authority
PA
Panama
Prior art keywords
same
substance
pharmaceutical composition
prostaglandinas
ocif
Prior art date
Application number
PA20038568001A
Other languages
English (en)
Inventor
Kumakura Seiichiro
Nakajima Tomoko
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of PA8568001A1 publication Critical patent/PA8568001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA NOVEDOSA QUE CONTIENE: (I) UN COMPLEJO QUE COMPRENDE POR LO MENOS UNA SUSTANCIA SELECCIONADA DEL GRUPO QUE CONSISTE DE FACTOR INHIBIDOR DE OSTEOCLASTOGENESIS (OCIF), ANALOGOS DEL MISMO Y VARIANTES DEL MISMO, EL CUAL SE UNE A POR LO MENOS UNA SUSTANCIA SELECCIONADA DEL GRUPO QUE CONSISTE DEL POLISACARIDOS Y DERIVADOS DE LOS MISMOS; Y (II) UNA SUSTANCIA QUE SUPRIME LA PRODUCCION DE PROSTAGLANDINAS Y/O UNA SUSTANCIA QUE COMPITE CON UNA ACCION BIOLOGICA DE PROSTAGLANDINAS, MUESTRA RETENCION PROLONGADA DE DICHO OCIF, ANALOGO DEL MISMO O VARIANTE DEL MISMO EN LA CORRIENTE SANGUINEA DESPUES DE SU ADMINISTRACION, ASI COMO ACTIVIDAD FARMACOLOGICA MEJORADA, HACIENDOLA UTIL EN EL TRATAMIENTO Y PROFILAXIS DE ENFERMEDADES METABOLICAS OSEAS.
PA20038568001A 2002-03-01 2003-02-27 Composicion farmaceutica PA8568001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002055356 2002-03-01

Publications (1)

Publication Number Publication Date
PA8568001A1 true PA8568001A1 (es) 2003-11-12

Family

ID=27784607

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038568001A PA8568001A1 (es) 2002-03-01 2003-02-27 Composicion farmaceutica

Country Status (7)

Country Link
US (2) US20030216297A1 (es)
EP (1) EP1482978A1 (es)
AR (1) AR038632A1 (es)
AU (1) AU2003208621A1 (es)
PA (1) PA8568001A1 (es)
TW (1) TW200303757A (es)
WO (1) WO2003074084A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
IL142557A0 (en) 1998-10-28 2002-03-10 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
PA8568001A1 (es) * 2002-03-01 2003-11-12 Sankyo Co Composicion farmaceutica
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
CN110753560B (zh) * 2017-04-11 2022-07-26 斯特劳曼控股公司 牙科植入物
CN113842464B (zh) * 2021-09-24 2023-07-04 江苏贝美医疗科技有限公司 一种类风湿因子吸附材料及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
ATE328281T1 (de) * 1997-09-24 2006-06-15 Sankyo Co Methode zur diagnose von abnormalem knochenstoffwechsel
AU4061899A (en) * 1998-06-15 2000-01-05 Takeda Chemical Industries Ltd. Thienodipyridine derivatives, production and use thereof
IL142557A0 (en) * 1998-10-28 2002-03-10 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
AU2262501A (en) * 1999-12-16 2001-06-25 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
PA8568001A1 (es) * 2002-03-01 2003-11-12 Sankyo Co Composicion farmaceutica

Also Published As

Publication number Publication date
US20030181418A1 (en) 2003-09-25
US20030216297A1 (en) 2003-11-20
TW200303757A (en) 2003-09-16
AU2003208621A1 (en) 2003-09-16
EP1482978A1 (en) 2004-12-08
AR038632A1 (es) 2005-01-19
WO2003074084A1 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
DE59811840D1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
TW200831112A (en) Compositions and methods for treatment of viral diseases
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
CL2010001123A1 (es) Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
PA8568001A1 (es) Composicion farmaceutica
PT1140031E (pt) Preparacao farmaceutica de libertacao controlada com mesilato de tilidina como substancia activa
CR11096A (es) Extrudidos con enmascaramiento del sabor mejorado
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
NO20064783L (no) Opplosningstabeletter med licarbazepin
AR071984A1 (es) Pregn-4-en-21,17 - carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen. proceso de obtencion
DE60325985D1 (de) Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
AR034716A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
NO985571L (no) Legemiddel for autoimmunsykdommer
AR042308A1 (es) Medicamento de administracion transdermica y transmucosica con absorcion mejorada de principios activos
TW200626133A (en) Oral medication for twice-daily administration
GT199800147A (es) Tetrahidronaftalenos substituidos y compuestos analogos.